GCTK net incomeQ2 2026-$3.81M
GCTK net income was -$3.81M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.76M a year earlier. For the full fiscal 2025 it was -$19.39M, compared with -$22.60M in fiscal 2024.
GlucoTrack Inc. (GCTK) financials
For the twelve months ended Jun 30, 2026, GlucoTrack Inc. reported -$15.95M of net income.
- Net income, TTM
- -$15.95M
- Cash
- $1.12M
- Market cap
- $954,873
FY2016FY2019
FY2016FY2025
FY2016FY2025
GCTK revenue and earnings growth
GCTK EPSQ2 2026$0.76
GCTK diluted EPS was $0.76 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was $31.22.
GCTK free cash flowQ4 2025-$3.96M
GCTK free cash flow was -$3.96M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$3.50M a year earlier. For the full fiscal 2025 it was -$15.34M, compared with -$12.59M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $208.0K | $43.5K | $589.5K | $611.7K |
| Research and development | $9.81M | $9.50M | $4.70M | $1.97M | $1.81M | $1.53M | $1.61M | $3.03M | $3.21M | $2.88M |
| Selling, general and admin | $6.28M | $5.05M | $2.28M | $2.46M | $2.09M | $415.0K | $1.53M | $2.46M | $6.43M | $1.13M |
| Operating income | -$16.09M | -$14.55M | -$7.10M | -$4.43M | -$4.04M | -$3.13M | $3.51M | -$6.54M | $10.58M | -$5.66M |
| Interest expense | - | $44.0K | - | - | - | - | - | - | - | - |
| Pre-tax income | - | - | - | - | - | -$2.70M | -$3.52M | -$6.72M | -$10.33M | -$5.41M |
| Net income | -$19.39M | -$22.60M | -$7.10M | -$4.43M | -$4.07M | -$2.70M | $3.52M | -$6.72M | $10.33M | -$5.41M |
| EPS, basic | $31.22 | $4106.00 | $34.18 | $0.29 | $0.26 | -$0.02 | -$0.02 | -$4.74 | -$1.87 | -$1.08 |
| EPS, diluted | $31.22 | $4106.00 | $34.18 | $0.29 | $0.26 | $0.19 | -$0.02 | -$4.74 | -$1.87 | -$1.08 |
| Diluted shares | 621,094 | 5,503 | 207,603 | 15.5M | 15.45B | 15.08B | 154.9M | 8.4M | 6.3M | 5.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.38M | $5.62M | $4.49M | $2.31M | $6.11M | $9.88M | $476.0K | $150.0K | $53.8K | $184.5K |
| Receivables | - | - | - | - | - | $66.0K | $70.0K | $22.8K | $121.8K | $92.1K |
| Inventory | - | - | - | - | - | $284.0K | $184.0K | $171.0K | $957.3K | $1.42M |
| Current assets | $7.67M | $5.77M | $4.87M | $2.38M | $6.11M | $10.23M | $718.0K | $314.1K | $1.23M | $2.02M |
| Total assets | $7.84M | $5.93M | $4.91M | $2.44M | $6.26M | $10.61M | $1.10M | $688.2K | $1.67M | $2.46M |
| Current liabilities | $4.77M | $1.27M | $1.51M | $1.01M | $883.0K | $1.34M | $2.27M | $3.22M | $3.69M | $2.35M |
| Total liabilities | $5.01M | $18.93M | $1.71M | $1.21M | $1.11M | $1.62M | $2.51M | $3.56M | $4.82M | $3.37M |
| Shareholders' equity | $2.83M | -$13.00M | $3.20M | $1.23M | $5.16M | $8.98M | -$1.41M | -$2.87M | -$16.57M | -$10.95M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.24M | -$12.49M | -$6.56M | -$3.73M | -$3.77M | -$3.50M | -$3.90M | -$4.89M | -$5.90M | -$5.31M |
| Capital expenditures | $96.0K | $104.0K | - | $1.0K | $5.0K | $53.0K | $23.0K | $5.4K | $19.5K | $76.5K |
| Free cash flow | -$15.34M | -$12.59M | - | -$3.73M | -$3.77M | -$3.55M | -$3.92M | -$4.90M | -$5.91M | -$5.39M |
| Investing cash flow | -$96.0K | -$104.0K | - | $1.0K | -$1.0K | -$53.0K | -$23.0K | -$5.4K | -$19.5K | -$76.5K |
| Financing cash flow | $17.04M | $13.74M | $8.73M | - | - | $13.01M | $4.20M | $4.96M | $5.75M | $4.94M |
| Stock-based compensation | $211.0K | $173.0K | $281.0K | $439.0K | $223.0K | $22.0K | $356.0K | $705.2K | $2.67M | $70.2K |
| Depreciation and amortization | - | - | - | - | $32.0K | $32.0K | - | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | 378.3% | -92.6% | -3.6% | 327.3% |
| EPS growth, YoY | - | - | - | - | 36.8% | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | 1685.6% | -15035.4% | 1794.2% | -924.6% |
| Net margin | - | - | - | - | - | - | 1690.4% | -15442.0% | 1752.2% | -884.4% |
| Free cash flow margin | - | - | - | - | - | - | -1885.6% | -11262.1% | -1003.4% | -880.9% |
| Return on equity | -685.6% | - | -222.0% | -360.6% | -78.9% | -30.0% | - | - | - | - |
| Return on assets | -247.4% | -380.9% | -144.7% | -181.9% | -64.9% | -25.4% | 320.8% | -975.8% | 618.9% | -219.8% |
| Current ratio | 1.61 | 4.52 | 3.22 | 2.35 | 6.91 | 7.61 | 0.32 | 0.10 | 0.33 | 0.86 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.02M | $2.13M | $1.63M | $3.17M | $3.15M | $1.87M | $1.70M | $2.06M | $3.59M | $2.15M | $1.74M | $1.69M |
| Selling, general and admin | $1.38M | $2.07M | $2.29M | $1.02M | $1.65M | $1.63M | $2.45M | $1.06M | $802.0K | $733.0K | $553.0K | $531.0K |
| Operating income | -$3.40M | -$4.20M | -$3.49M | -$4.31M | -$4.80M | -$3.50M | -$3.85M | -$3.25M | -$4.49M | -$2.95M | -$2.42M | -$2.22M |
| Interest expense | - | - | - | - | - | - | $39.0K | $5.0K | - | - | - | - |
| Net income | -$3.81M | -$4.33M | -$3.63M | -$4.17M | -$4.76M | -$6.83M | -$10.09M | -$5.09M | -$4.49M | -$2.93M | -$2.41M | -$2.22M |
| EPS, basic | $0.76 | $2.65 | - | $4.64 | $9.62 | $40.14 | - | $1092.00 | $984.00 | -$11.73 | - | -$0.49 |
| EPS, diluted | $0.76 | $2.65 | - | $4.64 | $9.62 | $40.14 | - | $1092.00 | $984.00 | -$11.73 | - | -$0.49 |
| Diluted shares | 5.0M | 1.6M | - | 899,410 | 494,504 | 169,345 | - | 4,663 | 4,564 | 249,598 | - | 4.6M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.12M | $3.93M | $7.38M | $7.87M | $9.55M | $9.10M | $5.62M | $346.0K | $159.0K | $1.50M | $4.49M | $6.89M |
| Current assets | $1.38M | $4.21M | $7.67M | $8.11M | $10.08M | $9.46M | $5.77M | $642.0K | $442.0K | $1.94M | $4.87M | $7.17M |
| Total assets | $1.50M | $4.36M | $7.84M | $8.29M | $10.21M | $9.61M | $5.93M | $826.0K | $608.0K | $2.11M | $4.91M | $7.20M |
| Current liabilities | $2.99M | $4.97M | $4.77M | $5.30M | $3.08M | $1.95M | $1.27M | $4.61M | $3.66M | $1.48M | $1.51M | $1.45M |
| Total liabilities | $3.24M | $5.21M | $5.01M | $5.54M | $3.33M | $2.35M | $18.93M | $4.85M | $3.90M | $1.73M | $1.71M | $1.64M |
| Shareholders' equity | -$1.74M | -$851.0K | $2.83M | $2.75M | $6.88M | $7.26M | -$13.00M | -$4.02M | -$3.29M | $375.0K | $3.20M | $5.56M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.62M | -$4.05M | -$3.94M | -$4.62M | -$3.74M | -$2.94M | -$3.50M | -$4.14M | -$1.91M | -$2.94M | -$2.41M | -$1.88M |
| Capital expenditures | - | - | $20.0K | $67.0K | $0 | $9.0K | $0 | $33.0K | $12.0K | $59.0K | - | - |
| Free cash flow | - | - | -$3.96M | -$4.69M | -$3.74M | -$2.95M | -$3.50M | -$4.17M | -$1.92M | -$3.00M | - | - |
| Investing cash flow | - | - | -$20.0K | -$67.0K | $0 | -$9.0K | $0 | -$33.0K | -$12.0K | -$59.0K | - | - |
| Financing cash flow | $803.0K | $591.0K | $3.49M | $2.99M | $4.16M | $6.39M | $8.78M | $4.38M | - | - | $0 | $0 |
| Stock-based compensation | $59.0K | $61.0K | $90.0K | $41.0K | $40.0K | $40.0K | -$66.0K | $11.0K | $206.0K | $22.0K | $21.0K | $31.0K |
| Depreciation and amortization | - | - | - | $9.0K | $11.0K | $8.0K | - | $10.0K | $8.0K | $4.0K | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.46 | 0.85 | 1.61 | 1.53 | 3.27 | 4.85 | 4.52 | 0.14 | 0.12 | 1.31 | 3.22 | 4.93 |
Source: XBRL data GlucoTrack Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
GCTK peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GCTK | - | - | -$15.95M | - | $954,873 |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |
GCTK FAQ
4 questionsIs GCTK profitable?
No. GlucoTrack Inc. reported a net loss of $15.95M for the twelve months ended Jun 30, 2026.How much cash and debt does GCTK have?
GlucoTrack Inc. reported $1.12M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did GCTK last report financial results?
The latest statements here come from GlucoTrack Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this GCTK financial data come from?
Quantisnow builds these statements from the structured XBRL data GlucoTrack Inc. files with the SEC. It is provided for information only and is not investment advice.